Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
124M
-
Number of holders
-
501
-
Total 13F shares, excl. options
-
124M
-
Shares change
-
+2.07M
-
Total reported value, excl. options
-
$7.1B
-
Value change
-
+$131M
-
Put/Call ratio
-
0.61
-
Number of buys
-
259
-
Number of sells
-
-202
-
Price
-
$57.24
Significant Holders of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) as of Q3 2024
555 filings reported holding HALO - HALOZYME THERAPEUTICS, INC. - Common Stock as of Q3 2024.
HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) has 501 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 124M shares
.
Largest 10 shareholders include BlackRock, Inc. (17.4M shares), VANGUARD GROUP INC (12.9M shares), STATE STREET CORP (6.63M shares), SNYDER CAPITAL MANAGEMENT L P (4.06M shares), ALLIANCEBERNSTEIN L.P. (3.41M shares), Artisan Partners Limited Partnership (3.13M shares), GEODE CAPITAL MANAGEMENT, LLC (3.06M shares), MACQUARIE GROUP LTD (3.01M shares), JPMORGAN CHASE & CO (2.86M shares), and CONGRESS ASSET MANAGEMENT CO (2.43M shares).
This table shows the top 501 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.